Incyte Corporation
INCY
Jodie situation report
Incyte Corporation's move is spreading beyond its market group.
INCY accounts for 1.6% of the group's measured movement across 9.8 effective names. all 12 measured members are falling in raw terms, but 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 41%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
GILD, NBIX, GSK moved materially before INCY. INCY crossed its material path threshold at 13:25 ET, 85 minutes after the first measured mover. MRK followed.
- Revenue increased 20.9% versus the comparable filing period.
8 of 15 members in Biopharmaceuticals and Care are active. 0 of 8 disclosed connections are confirming.
- At least 10 of 15 durable members become active together.
- Capital-flow agreement rises above 55%.
- ABBV remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 5 of 15 members or fewer.
Who this business touches
The relationships behind INCY
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
SNDXSyndax Pharmaceuticals, Inc.partnerApr 28, 2026 ▾
“In addition to establishing collaborative or license arrangements under which other parties license our drug candidates for development and commercialization or under which we study our drug candidates in combination with such parties’ compounds or biologics,…”
MGNXFiling-linked namepartnerApr 28, 2026 ▾
“In addition to establishing collaborative or license arrangements under which other parties license our drug candidates for development and commercialization or under which we study our drug candidates in combination with such parties’ compounds or biologics,…”
Depended on by
SNDXSyndax Pharmaceuticals, Inc.partnerApr 30, 2026 ▾
“We are leading the commercialization and further development of revumenib and working closely with our collaboration partner, Incyte, on the commercialization and further development of axatilimab.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 20 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
INCY is currently a Participant in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.